Immunoglobulin Gene Polymorphisms Are Susceptibility Factors in Clinical and Autoantibody Subgroups of the Idiopathic Inflammatory Myopathies

National Institute of Environmental Health Sciences, NIH, Bethesda, Maryland 20892, USA.
Arthritis & Rheumatology (Impact Factor: 7.87). 10/2008; 58(10):3239-46. DOI: 10.1002/art.23899
Source: PubMed

ABSTRACT To investigate possible associations of GM and KM markers with adult and juvenile forms of the idiopathic inflammatory myopathies (IIMs) in Caucasian and African American patients.
We performed serologic analyses of polymorphic determinants associated with immunoglobulin gamma heavy chains (GM) and kappa light chains (KM) in large populations of Caucasian patients (n= 514 [297 adults and 217 children]) and African American patients (n=123 [73 adults and 50 children]) with IIM representing the major clinical and autoantibody groups.
For Caucasian patients with dermatomyositis (DM), the Gm 3 23 5,13 phenotype was a risk factor in both adults (odds ratio [OR] 2.2, corrected P [Pcorr]=0.020) and children (OR 2.2, Pcorr=0.0013). Of interest, the GM 13 allotype was a risk factor for juvenile DM in both Caucasian subjects (OR 3.9, Pcorr<0.0001) and African American subjects (OR 4.8, Pcorr=0.033). However, the Gm 1,3,17 5,13,21 phenotype was a risk factor for juvenile DM in Caucasian subjects but not African American subjects. Among the IIM autoantibody groups, Gm 3 23 5,13 was a risk factor in Caucasian adults with anti-Jo-1 autoantibodies (OR 3.4, Pcorr=0.0031), while the GM 3 allotype was protective in adults with anti-threonyl-transfer RNA synthetase or anti-U RNP autoantibodies (OR 0.1, Pcorr=0.047 and OR 0.2, Pcorr=0.034, respectively). In contrast, GM 6 was a risk factor in African American adults with anti-signal recognition particle autoantibodies (OR 7.5, Pcorr=0.041).
These data suggest that polymorphic alleles of GM and KM loci are differentially associated with IIM subgroups defined by age, ethnicity, clinical features, and autoantibody status, and expand the list of immune response genes that are possibly important in the pathogenesis of myositis.

Download full-text


Available from: Lisa G. Rider Md, Aug 20, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although it has been long recognized that inflammatory muscle disease of unknown etiology may present clinically and respond to therapy in a variety of ways, our approaches regarding how to best classify or divide these entities into more understandable groups of patients has evolved as larger series have been studied using advanced laboratory, immunopathologic, and genetic technologies. In addition to the traditional clinicopathologic classifications of these entities, there is increasing interest in using newer methods, including serology, environmental exposures, and molecular genetics, to divide these syndromes into more homogeneous subsets. While our understanding of these disorders is far from complete, it is clear that the inflammatory myopathies are composed of many separate and distinct disorders with widely divergent clinical signs, symptoms, pathology, laboratory abnormalities, immune responses, genetic and environmental risk factors, and prognoses. Classification of the inflammatory myopathies remains unsatisfactory and controversial, with a number of competing approaches currently in use. Nonetheless, while many different schemes have been proposed, this chapter focuses on the classifications based on clinical signs, pathology, and autoantibodies that today are useful in assessing subjects, as well as possible new approaches that take into account environmental exposures and immunogenetics. Our understanding of the pathogenesis, classification, and prognosis of the inflammatory myopathies will become more complete as we decipher the interrelationships among all the critical features of disease—including the genetic and environmental risk factors necessary and sufficient for the induction of myositis—and develop more rational ways of dividing and treating these increasingly recognized syndromes. KeywordsClinicopathologic–Serologic–Myositis-specific autoantibodies–Environmental–Genetic–Phenotypes
    06/2009: pages 15-28;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The idiopathic inflammatory myopathies, or myositis syndromes, are heterogeneous autoimmune diseases defined by chronic muscle inflammation of unknown cause. They likely develop after the interaction of genetic and environmental risk factors in the absence of protective factors. The known genetic risk and protective factors are common alleles at polymorphic immune response loci and vary depending on phenotype. Furthermore, genetic associations are stronger with phenotypes defined by clinical features and autoantibodies than with myositis patients as a whole. Genetic factors for myositis also vary by age of onset, ethnicity, and environmental exposure group. Of interest, risk genes for one phenotype are often protective for another, possibly explaining the mutual exclusivity of many myositis subgroups. International collaborations using genome-wide association studies are needed to identify additional genes, gene-gene, and gene-environment interactions, all of which have pathogenic, therapeutic, and preventative implications for these increasingly recognized disorders.
    Current Rheumatology Reports 09/2009; 11(4):287-94. DOI:10.1007/s11926-009-0040-2 · 2.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La dermatomiositis es un tipo de miopatía inflamatoria idiopática que afecta al músculo esquelético y a la piel. Los objetivos de esta revisión son, en primer lugar, dar una pincelada breve sobre las manifestaciones cutáneas de la enfermedad para los que no estén tan familiarizados con éstas; en segundo lugar, plantear algunas cuestiones aún debatidas sobre la dermatomiositis amiopática, y, en tercer lugar, revisar un aspecto muy interesante como es el de la dermatomiositis y el riesgo de desarrollo de neoplasia. Respecto a este último punto, está claro que los pacientes con dermatomiositis tienen un mayor riesgo de desarrollo de una neoplasia y si bien no hay marcadores clínicos o biológicos claros de la presencia de ésta, es posible que en un futuro próximo se pueda disponer de autoanticuerpos que puedan desempeñar este importante papel.
    Reumatología Clínica 09/2009; DOI:10.1016/j.reuma.2008.09.004
Show more